ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR)

Historical Holders from Q3 2014 to Q3 2025

Symbol: PRQR on Nasdaq
Type / Class: Equity / Ordinary Shares, nominal value Euro 0.04 per share
Shares outstanding: 105,365,368
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 37,542,716
Holdings value: $79,967,112
% of all portfolios: 0%
Number of holders: 63
Number of buys: 21
Number of sells: -18
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VAN HERK INVESTMENTS B.V.	13.6%	+7.69%	$31,668,615	+$2,331,550	14,329,690	+7.95%	Van Herk Investments B.V.	29 Sep 2025
Adage Capital Management, L.P.	6.27%	-17.9%	$13,467,954	-$3,060,326	6,601,938	-18.5%	Adage Capital Management, L.P.	30 Jun 2025

Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	37,542,716	$79,967,112	-$6,233,021		$0	$2.13	63
2025 Q2	40,456,202	$82,379,793	-$1,567,785	$0	$53,040	$2.04	61
2025 Q1	41,291,570	$54,918,956	-$5,787,635	$7,049	$40,033	$1.33	63
2024 Q4	44,407,421	$117,680,021	+$75,460,221	$65,455	$83,210	$2.65	74
2024 Q3	17,443,866	$31,743,198	+$264,549	$38,766	$68,614	$1.82	45
2024 Q2	17,290,486	$28,649,850	-$212,174	$14,276	$43,492	$1.66	47
2024 Q1	17,387,392	$39,773,390	-$2,337,680	$26,786	$119,175	$2.29	48
2023 Q4	18,391,369	$36,955,484	-$454,962	$3,168	$46,332	$1.98	46
2023 Q3	18,716,181	$24,328,704	-$3,600,695	$0	$0	$1.30	45
2023 Q2	21,135,686	$34,237,327	-$2,196,851	$22,518	$225,990	$1.62	50
2023 Q1	22,322,571	$47,544,921	+$11,107,713	$385,104	$459,228	$2.13	54
2022 Q4	16,678,999	$59,949,585	-$4,474,620	$434,010	$275,280	$3.70	44
2022 Q3	21,236,882	$15,861,034	-$760,592		$28,000	$0.7440	42
2022 Q2	22,126,805	$17,208,344	-$8,963,813	$0	$71,000	$0.7779	47
2022 Q1	31,740,344	$28,730,297	-$92,041,029	$48,319	$1,236,130	$0.9052	56
2021 Q4	45,445,352	$364,779,631	+$6,635,516	$302,000	$212,000	$8.01	72
2021 Q3	39,831,678	$333,392,000	+$12,212,303	$1,010,000	$880,000	$8.37	65
2021 Q2	38,480,445	$259,361,000	-$31,879,222	$199,000	$202,000	$6.74	61
2021 Q1	43,321,891	$286,357,000	+$115,578,874	$1,236,000	$870,000	$6.61	63
2020 Q4	26,413,704	$110,936,100	-$6,602,420	$71,000		$4.20	46
2020 Q3	19,690,795	$94,319,000	-$5,245,378	$2,000	$0	$4.79	21
2020 Q2	29,107,854	$176,974,000	-$802,484	$16,000	$131,000	$6.08	43
2020 Q1	29,335,757	$161,049,000	-$7,183,294	$113,000	$77,000	$5.49	43
2019 Q4	30,150,188	$298,791,000	+$87,234,363			$9.91	51
2019 Q3	21,662,331	$124,772,000	-$19,145,910			$5.76	49
2019 Q2	23,626,883	$215,004,000	-$8,675,469			$9.10	55
2019 Q1	24,000,014	$332,879,291	+$6,357,080			$13.87	54
2018 Q4	23,104,591	$364,447,000	+$50,602,846			$15.78	57
2018 Q3	19,515,607	$377,636,000	+$168,574,699			$19.35	35
2018 Q2	11,069,586	$80,808,000	+$5,443,350			$7.30	24
2018 Q1	10,687,432	$32,865,000	-$2,756,918			$3.08	23
2017 Q4	11,508,113	$37,112,000	+$4,385,460			$3.22	26
2017 Q3	10,077,120	$48,873,000	+$5,139,062			$4.85	22
2017 Q2	9,002,972	$46,815,000	+$1,971,549			$5.20	17
2017 Q1	9,010,116	$45,050,000	+$634,080			$5.00	20
2016 Q4	8,889,119	$43,557,000	+$395,680			$4.90	22
2016 Q3	8,692,509	$57,980,000	-$2,944,700			$6.67	25
2016 Q2	9,151,395	$44,281,000	-$2,331,016			$4.84	26
2016 Q1	9,632,100	$46,949,000	-$10,777,157			$4.88	29
2015 Q4	11,189,723	$97,062,000	-$3,472,581			$8.68	32
2015 Q3	11,137,806	$162,244,000	+$3,974,891			$14.57	35
2015 Q2	10,835,771	$180,597,000	-$5,671,266			$16.67	36
2015 Q1	11,013,755	$241,353,000	+$65,737,809			$21.88	38
2014 Q4	8,018,201	$172,936,000	+$8,842,888			$21.67	35
2014 Q3	7,627,734	$129,886,000	+$129,886,000			$17.19	30